A number of articles have been published on RANK, RANK Ligand and osteoprogeterin (OPG) since Amgen’s identification of OPG and the RANK Ligand signaling pathway in the 1990s. Amgen provides links to these publications as a resource to media. However, Amgen takes no responsibility for, and exercises no control over, the accuracy of the information contained on any external server or site.
Information in this table can be sorted by Author, Title or Journal. Click on column headings to sort.
Author |
Title | Journal | Abstract | ||||
|---|---|---|---|---|---|---|---|
| Akatsu T, Murakami T, Nishikawa M, et al. | Osteoclastogenesis inhibitory factor suppresses osteoclast survival by interfering in the interaction of stromal cells with osteoclast. | Biochem Biophys Res Comm. 1998;250:229-234. | View PubMed Abstract | ||||
| Anderson DM, Maraskovsky E, Billingsley WL, et al. | A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. | Nature. 1997;390:175-179. | View PubMed Abstract | ||||
| Atkins GJ, Bouralexis S, Haynes DR, et al. | Osteoprotegerin inhibits osteoclast formation and bone resorbing activity in giant cell tumors of bone. | Bone. 2001;28:370-377. | View PubMed Abstract | ||||
| Barkin R. | Perception, assessment, treatment, and management of pain in the elderly. | Clinics in Geriatric Medicine. Philadelphia, PA: W.B. Saunders Company; 2005. | View PubMed Abstract | ||||
| Baum M, Budzar AU, Cuzick J, et al. | Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. | Lancet. 2002;359:2131-2139. | View PubMed Abstract | ||||
| Bekker PJ, Holloway D, Nakanishi A, et al. | The effect of a single dose of osteoprotegerin in postmenopausal women. | J Bone Min Res. 2001;16:348-360. | View PubMed Abstract | ||||
| Body JJ, Greipp P, Coleman RE, et al. | A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. | Cancer. 2003;97(3 suppl):887-892. | View PubMed Abstract | ||||
| Boyle WJ, Simonet WS, Lacey DL. | Osteoclast differentiation and activation. | Nature. 2003;423:337-342. | View PubMed Abstract | ||||
| Bucay N, Sarosi I, Dunstan CR, et al. | Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. | Genes Dev. 1998;12:1260-1268. | View PubMed Abstract | ||||
| Burgess TL, Qian Y, Kaufman S, et al. | The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. | J Cell Biol. 1999;145:527-538. | View PubMed Abstract | ||||
| Campagnuolo G, Bolon B, Feige U. | Kinetics of bone protection by recombinant osteoprotegerin therapy in Lewis rats with adjuvant arthritis. | Arthritis Rheum. 2002;46:1926-1936. | View PubMed Abstract | ||||
| Campion, JM. | Osteoporosis in men. | Am Fam Physic. 2003;67:1521-1526. | View PubMed Abstract | ||||
| Capparelli C, Morony S, Warmington K, et al. | Sustained antiresorptive effects after a single treatment with human recombinant osteoprotegerin (OPG): a pharmacodynamic and pharmacokinetic analysis in rats. | J Bone Min Res. 2003;18:852-858. | View PubMed Abstract | ||||
| Conde FA, Aronson WJ. | Risk factors for male osteoporosis. | Urol Oncol. 2003;21:380-383. | View PubMed Abstract | ||||
| Croucher PI, Shipman CM, Lippitt J, et al. | Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. | Blood. 2001;98:3534-3540. | View PubMed Abstract | ||||
| Eastell R. | Treatment of postmenopausal osteoporosis. | New Engl J Med. 1998;736-746. | View PubMed Abstract | ||||
| Eghbali-Fatourechi G, Khosla S, Sanyal A, et al. | Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. | J Clin Invest. 2003;111:1221-1230. | View PubMed Abstract | ||||
| Faruggia AN, Atkins GJ, To LB, et al. | Receptor activator of nuclear factor-KappaB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo. | Cancer Res. 2003;63:5438-5445. | View PubMed Abstract | ||||
| Fata JE, et al. | The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. | Cell. 2000:103:41-50. | View PubMed Abstract | ||||
| Fidler IJ. | The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. | Nat Rev Cancer. 2003;3:453 – 458. | View PubMed Abstract | ||||
| Fuller K, Wong B, Fox S, Choi Y, Chambers TJ. | TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. | J Exp Med. 1998;188:997-1001. | View PubMed Abstract | ||||
| Goss PE, Strasser K. | Aromatase inhibitors in the treatment and prevention of breast cancer. | J Clin Oncol. 2001;19:881-894. | View PubMed Abstract | ||||
| Grassi W, De Angelis R, Lamanna G, Cervini C. | The clinical features of rheumatoid arthritis. | Eur J Radiol. 1998:27(suppl 1):S18-S24. | View PubMed Abstract | ||||
| Hillner BE, Ingle JN, Chlebowski RT, et al. | American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. | J Clin Oncol. 2003;21:4042-4057. | View PubMed Abstract | ||||
| Hofbauer LC, Gori F, Riggs BL, et al. | Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. | Endocrinology. 1999;140:4382-4389. | View PubMed Abstract | ||||
| Hofbauer LC, Khosla S, Dunstan CR, et al. | Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. | Endocrinology. 1999;140:4367-4370. | View PubMed Abstract | ||||
| Hofbauer LC, Schoppet M. | Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. | JAMA. 2004;292:490-495. | View PubMed Abstract | ||||
| Honore P, Luger NM, Sabino MAC, et al. | Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. | Nat Med. 2000;6:521-528. | View PubMed Abstract | ||||
| Hsu H, et al. | Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. | Proc Natl Acad Sci. 1999:96:3540-3545. | View PubMed Abstract | ||||
| Ichinose Y, Tanaka H, Inoue N, Mochizuki S, Tsuda E, Seino Y. | Osteoclastogenesis inhibitory factor/osteoprotegerin reduced bone loss induced by mechanical unloading. | Calc Tissue Intl. 2004;75:338-343. | View PubMed Abstract | ||||
| Kessler B. | The natural history of prostate cancer. | Urol Clin North Am. 2003;30:219-226. | View PubMed Abstract | ||||
| Kitazawa S, Kitazawa R. | RANK ligand is a prerequisite for cancer-associated osteolytic lesions. | J Pathol. 2002;198:228-236. | View PubMed Abstract | ||||
| Kong YY, Yoshida H, Sarosi I, et al. | OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. | Nature. 1999;397:315-323. | View PubMed Abstract | ||||
| Kostenuik PJ, Capparelli C, Morony S, et al. | OPG and PTH-(1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats. | Endocrinology. 2001;142:4295-4304. | View PubMed Abstract | ||||
| Laan RF, van Riel PL, van de Putte LB, van Erning LJ, van ’ t Hof MA, Lemmens JA. | Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. A randomized, controlled study. | Ann Intern Med. 1993;119:963-968. | View PubMed Abstract | ||||
| Lacey DL, Tan HL, Lu J, et al. | Osteoprotegerin ligand modulates murine oseoclast survival in vitro and in vivo. | Am J Pathol. 2000;157:435-448. | View PubMed Abstract | ||||
| Lacey DL, Timms E, Tan HL, et al. | Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. | Cell. 1998;93:165-176. | View PubMed Abstract | ||||
| Lahtinen R, Laakso M, Palva I, Virkkunen P, Elomaa I. | Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group. | Lancet. 1992;340:1049-1052. | View PubMed Abstract | ||||
| Lindqvist E, Jonsson K, Saxne T, Eberhardt K. | Course of radiographic damage over 10 years in a cohort with early rheumatoid arthritis. | Ann Rheum Dis. 2003;62:611-616. | View PubMed Abstract | ||||
| Luger NM, Honore P, Sabino MAC, et al. | Osteoprotegerin diminishes advanced bone cancer pain. | Cancer Res. 2001;61:4038-4047. | View PubMed Abstract | ||||
| Lukert BP, Raisz LG. | Glucocorticoid-induced osteoporosis: pathogenesis and management. | Ann Intern Med. 1990;112:352-364. | View PubMed Abstract | ||||
| Maalouf NM, Shane E. | Osteoporosis after solid organ transplantation. | J Clin Endo Metab. 2005;90:2456-2465. | View PubMed Abstract | ||||
| Melton LJ III, Alothman KI, Khosla S, Achenbach SJ, Oberg AL, Zincke H. | Fracture risk following bilateral orchiectomy. | J Urol. 2003;169:1747-1750. | View PubMed Abstract | ||||
| Melton LJ III. | Epidemiology worldwide. | Endocrinology and Metabolism Clinics. Philadelphia, PA: W. B. Saunders Company; 2003;1-13. | View PubMed Abstract | ||||
| Mirza F. | Bone health and aging: implications for menopause. | Endocrinology and Metabolism Clinics. Philadelphia, PA: W. B. Saunders Company; 2004. | View PubMed Abstract | ||||
| Mizuno A, Amizuka N, Irie K, et al. | Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. | Biochem Biophys Res Commun. 1998;247:610-615. | View PubMed Abstract | ||||
| Mochizuki S, Fujise N, Higashio K, Tsuda E. | Osteoclastogenesis inhibitory factor/osteoprotegerin ameliorates the decrease in both bone mineral density and bone strength in immobilized rats. | J Bone Min Metab. 2002;20:14-20. | View PubMed Abstract | ||||
| Morony S, Capparelli C, Sarosi I, Lacey DL, Dunstan CR, Kostenuik PJ. | Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. | Cancer Res. 2001;61:4432-4436. | View PubMed Abstract | ||||
| Mundy GR. | Metastasis to bone: causes, consequences and therapeutic opportunities. | Nat Rev Cancer. 2002;2:584-593. | View PubMed Abstract | ||||
| Nelson HD, Helfand M, Woolf SH, Allan JD. | Screening for postmenopausal osteoporosis: a review of the evidence for the U.S. Preventive Services Task Force. | Ann Intern Med. 2002;137:529-541. | View PubMed Abstract | ||||
| O’Brien EA, Williams JHH, Marshall MJ. | Osteoprotegerin ligand regulates osteoclast adherence to the bone surface in mouse calvaria. | Biochem Biophys Res Commun. 2000;274:281-290. | View PubMed Abstract | ||||
| Palmer SC, Strippoli GFM, McGregor DO. | Interventions for preventing bone disease in kidney transplant recipients: a systematic review of randomized controlled trials. | Am J Kid Dis. 2005;45:638-649. | View PubMed Abstract | ||||
| Pearse RN, Sordillo EM, Yaccoby S, et al. | Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. | Proc Natl Acad Sci U.S.A. 2001;98:11581-11586. | View PubMed Abstract | ||||
| Roodman GD. | Mechanisms of bone metastasis. | N Engl J Med. 2004;350:1655-1664. | View PubMed Abstract | ||||
| Ross AB, Bateman TA, Kostenuik PJ, et al. | The effects of osteoprotegerin on the mechanical properties of rat bone. | J Mater Sci Mater Med. 2001;12:583-588. | View PubMed Abstract | ||||
| Sanders JL, Chattopadhyay N, Kifor O, Yamaguchi T, Butters RR, Brown EM. | Extracellular calcium-sensing receptor expression and its potential role in regulating parathyroid hormone-related peptide secretion in human breast cancer cell lines. | Endocrinology. 2000;141:4357-4364. | View PubMed Abstract | ||||
| Sasaki N, Kusano E, Ando Y, Yano K, Tsuda E, Asano Y. | Glucocorticoid decreases circulating osteoprotegerin (OPG): possible mechanism for glucocorticoid induced osteoporosis. | Nephrol Dial Transplant. 2001;16:479-482. | View PubMed Abstract | ||||
| Schett G, Redlich K, Hayer S, et al. | Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice. | Arthritis Rheum. 2003;48:2042-2051. | View PubMed Abstract | ||||
| Sezer O, Heider U, Jakob C, Eucker J, Possinger K. | Human bone marrow myeloma cells express RANKL. | J Clin Oncol. 2002;20:353-354. | View PubMed Abstract | ||||
| Smith BB, Cosenza ME, Mancini A, et al. | A toxicity profile of osteoprotegerin in the cynomolgus monkey. | Intl J Toxicol. 2003;22:403-412. | View PubMed Abstract | ||||
| Smith MR, McGovern FJ, Zietman AL, et al. | Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. | N Engl J Med. 2001;345:948-955. | View PubMed Abstract | ||||
| Stilgren LS, Rettmer E, Eriksen EF, Hegedus L, Beck-Nielsen H, Abrahamsen B. | Skeletal changes in osteoprotegerin and receptor activator of nuclear factor-kb ligand mRNA levels in primary hyperparathyroidism; effect of parathyroidectomy and association with bone metabolism. | Bone. 2004;35:256-265. | View PubMed Abstract | ||||
| Stoch SA, Parker RA, Chen L, et al. | Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists. | J Clin Endocrinol Metab. 2001;86:2787-2791. | View PubMed Abstract | ||||
| Stolina M, et al. | RANKL is a marker and mediator of local and systemic bone loss. | J Bone Miner Res. 2005;20(10):1756-1765. | View PubMed Abstract | ||||
| Thomas RJ, Gulse TA, Yin JJ, et al. | Breast cancer cells interact with osteoblasts to support osteoclast formation. | Endocrinology. 1999;140:4451-4458. | View PubMed Abstract | ||||
| Vanderkerken K, De Leenheer ED, Shipman C, et al. | Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma. | Cancer Research. 2003;63:287-289. | View PubMed Abstract | ||||
| Wehren L. | The epidemiology of osteoporosis and fractures in geriatric medicine. | Clin Geriatr Med. 2003;19:245-258. | View PubMed Abstract | ||||
| Yasuda H, Shima N, Nakagawa N, et al. | Osteoclast differentiation factor is a ligand for osteoprotegerin/ osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. | Proc Natl Acad Sci USA. 1998;95:3597-3602. | View PubMed Abstract | ||||
| Yuan YY, Lau AG, Kostenuik PJ, et al. | RANKL has detrimental effects on cortical and trabecular bone volume, mineralization, and bone strength in mice. | Poster presentation at Bone Quality 2005 meeting, held May 2-3, 2005, in Bethesda, MD. | No Abstract Available | ||||
